CMS发布关于第三轮医疗保险药品价格谈判计划的草案指导意见

Core Insights - The Centers for Medicare & Medicaid Services (CMS) has released draft guidance for the third round of Medicare drug price negotiation, focusing on improving negotiation transparency and prioritizing high-cost prescription drugs for inclusion in Medicare [1] Group 1 - The guidance aims to enhance the transparency of the negotiation process for drug prices [1] - It emphasizes the selection of high-cost prescription drugs to be included in Medicare negotiations [1] - The policy seeks to minimize any negative impact that negotiated fair maximum prices may have on drug innovation in the United States [1]